Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer.

Boekel NB, Jacobse JN, Schaapveld M, Hooning MJ, Gietema JA, Duane FK, Taylor CW, Darby SC, Hauptmann M, Seynaeve CM, Baaijens MHA, Sonke GS, Rutgers EJT, Russell NS, Aleman BMP, van Leeuwen FE.

Br J Cancer. 2018 Aug 1. doi: 10.1038/s41416-018-0159-x. [Epub ahead of print]

PMID:
30065254
2.

Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.

Groot HJ, Lubberts S, de Wit R, Witjes JA, Kerst JM, de Jong IJ, Groenewegen G, van den Eertwegh AJM, Poortmans PM, Klümpen HJ, van den Berg HA, Smilde TJ, Vanneste BGL, Aarts MJ, Incrocci L, van den Bergh ACM, Jóźwiak K, van den Belt-Dusebout AW, Horenblas S, Gietema JA, van Leeuwen FE, Schaapveld M.

J Clin Oncol. 2018 Aug 20;36(24):2504-2513. doi: 10.1200/JCO.2017.77.4174. Epub 2018 Jul 10.

PMID:
29989856
3.

Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ-A Nested Case-Control Study.

Visser LL, Elshof LE, Schaapveld M, van de Vijver K, Groen EJ, Almekinders MM, Bierman C, van Leeuwen FE, Rutgers EJ, Schmidt MK, Lips EH, Wesseling J.

Clin Cancer Res. 2018 Aug 1;24(15):3593-3601. doi: 10.1158/1078-0432.CCR-18-0201. Epub 2018 Apr 23.

PMID:
29685879
4.

High burden of subsequent malignant neoplasms and cardiovascular disease in long-term Hodgkin lymphoma survivors.

de Vries S, Schaapveld M, van Nimwegen FA, Jóźwiak K, Lugtenburg PJ, Daniëls LA, Roesink JM, van der Maazen RWM, Kok WEM, Aleman BMP, van Leeuwen FE.

Br J Cancer. 2018 Mar 20;118(6):887-895. doi: 10.1038/bjc.2017.476. Epub 2018 Jan 30.

PMID:
29381685
5.

Increased colon cancer risk after severe Salmonella infection.

Mughini-Gras L, Schaapveld M, Kramers J, Mooij S, Neefjes-Borst EA, Pelt WV, Neefjes J.

PLoS One. 2018 Jan 17;13(1):e0189721. doi: 10.1371/journal.pone.0189721. eCollection 2018.

6.

Breast Cancer Risk After Radiation Therapy for Hodgkin Lymphoma: Influence of Gonadal Hormone Exposure.

Krul IM, Opstal-van Winden AWJ, Aleman BMP, Janus CPM, van Eggermond AM, De Bruin ML, Hauptmann M, Krol ADG, Schaapveld M, Broeks A, Kooijman KR, Fase S, Lybeert ML, Zijlstra JM, van der Maazen RWM, Kesminiene A, Diallo I, de Vathaire F, Russell NS, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):843-853. doi: 10.1016/j.ijrobp.2017.07.016. Epub 2017 Jul 18.

PMID:
28888722
7.

Response to: "DCIS and Breast Cancer: Challenging the Paradigm".

Schaapveld M, Wesseling J.

Ann Surg. 2018 Jul;268(1):e18. doi: 10.1097/SLA.0000000000002418. No abstract available.

PMID:
28697052
8.

Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors.

van Eggermond AM, Schaapveld M, Janus CP, de Boer JP, Krol AD, Zijlstra JM, van der Maazen RW, Kremer LC, van Leerdam ME, Louwman MW, Visser O, De Bruin ML, Aleman BM, van Leeuwen FE.

Br J Cancer. 2017 Jul 25;117(3):306-314. doi: 10.1038/bjc.2017.177. Epub 2017 Jun 20.

9.

Cause-specific Mortality in a Population-based Cohort of 9799 Women Treated for Ductal Carcinoma In Situ.

Elshof LE, Schmidt MK, Rutgers EJT, van Leeuwen FE, Wesseling J, Schaapveld M.

Ann Surg. 2018 May;267(5):952-958. doi: 10.1097/SLA.0000000000002239.

10.

The method of detection of ductal carcinoma in situ has no therapeutic implications: results of a population-based cohort study.

Elshof LE, Schaapveld M, Rutgers EJ, Schmidt MK, de Munck L, van Leeuwen FE, Wesseling J.

Breast Cancer Res. 2017 Mar 9;19(1):26. doi: 10.1186/s13058-017-0819-4.

11.

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines.

van Nimwegen FA, Ntentas G, Darby SC, Schaapveld M, Hauptmann M, Lugtenburg PJ, Janus CPM, Daniels L, van Leeuwen FE, Cutter DJ, Aleman BMP.

Blood. 2017 Apr 20;129(16):2257-2265. doi: 10.1182/blood-2016-09-740332. Epub 2017 Jan 31.

12.

Erratum to: Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J.

Breast Cancer Res Treat. 2017 Jan;161(2):389-390. doi: 10.1007/s10549-016-4060-0. No abstract available.

PMID:
27878644
13.

Survival differences between patients with Hodgkin lymphoma treated inside and outside clinical trials. A study based on the EORTC-Netherlands Cancer Registry linked data with 20 years of follow-up.

Liu L, Giusti F, Schaapveld M, Aleman B, Lugtenburg P, Meijnders P, Hutchings M, Lemmens V, Bogaerts J, Visser O.

Br J Haematol. 2017 Jan;176(1):65-75. doi: 10.1111/bjh.14379. Epub 2016 Oct 21.

PMID:
27766636
14.

Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women.

Elshof LE, Schaapveld M, Schmidt MK, Rutgers EJ, van Leeuwen FE, Wesseling J.

Breast Cancer Res Treat. 2016 Oct;159(3):553-63. doi: 10.1007/s10549-016-3973-y. Epub 2016 Sep 8. Erratum in: Breast Cancer Res Treat. 2017 Jan;161(2):389-390.

15.

Reply to D. Vordermark and T. Pelz and R. Mazzola et al.

van Nimwegen FA, Cutter DJ, Schaapveld M, Darby SC, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2016 Aug 20;34(24):2941-2. doi: 10.1200/JCO.2016.67.4358. Epub 2016 May 2. No abstract available.

PMID:
27138579
16.

Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors.

Boekel NB, Schaapveld M, Gietema JA, Russell NS, Poortmans P, Theuws JC, Schinagl DA, Rietveld DH, Versteegh MI, Visser O, Rutgers EJ, Aleman BM, van Leeuwen FE.

Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1061-72. doi: 10.1016/j.ijrobp.2015.11.040. Epub 2015 Dec 14.

PMID:
27026313
17.

Employment and social benefits up to 10 years after breast cancer diagnosis: a population-based study.

Paalman CH, van Leeuwen FE, Aaronson NK, de Boer AG, van de Poll-Franse L, Oldenburg HS, Schaapveld M.

Br J Cancer. 2016 Jan 12;114(1):81-7. doi: 10.1038/bjc.2015.431.

18.

Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma.

Schaapveld M, Aleman BM, van Eggermond AM, Janus CP, Krol AD, van der Maazen RW, Roesink J, Raemaekers JM, de Boer JP, Zijlstra JM, van Imhoff GW, Petersen EJ, Poortmans PM, Beijert M, Lybeert ML, Mulder I, Visser O, Louwman MW, Krul IM, Lugtenburg PJ, van Leeuwen FE.

N Engl J Med. 2015 Dec 24;373(26):2499-511. doi: 10.1056/NEJMoa1505949.

19.

Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma.

van Nimwegen FA, Schaapveld M, Cutter DJ, Janus CP, Krol AD, Hauptmann M, Kooijman K, Roesink J, van der Maazen R, Darby SC, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2016 Jan 20;34(3):235-43. doi: 10.1200/JCO.2015.63.4444. Epub 2015 Nov 16.

PMID:
26573075
20.

Cause-specific excess mortality in patients treated for cancer of the oral cavity and oropharynx: A population-based study.

van Monsjou HS, Schaapveld M, Hamming-Vrieze O, de Boer JP, van den Brekel MW, Balm AJ.

Oral Oncol. 2016 Jan;52:37-44. doi: 10.1016/j.oraloncology.2015.10.013. Epub 2015 Nov 6.

PMID:
26553390
21.

Current knowledge and future research directions in treatment-related second primary malignancies.

Morton LM, Swerdlow AJ, Schaapveld M, Ramadan S, Hodgson DC, Radford J, van Leeuwen FE.

EJC Suppl. 2014 Jun;12(1):5-17. doi: 10.1016/j.ejcsup.2014.05.001. Epub 2014 May 29.

22.

The epidemiology of head and neck squamous cell carcinoma in The Netherlands during the era of HPV-related oropharyngeal squamous cell carcinoma. Is there really evidence for a change?

van Monsjou HS, Schaapveld M, van den Brekel MW, Balm AJ.

Oral Oncol. 2015 Oct;51(10):901-7. doi: 10.1016/j.oraloncology.2015.06.011. Epub 2015 Jul 26.

PMID:
26216340
23.

Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Petersen EJ, Raemaekers JM, Kok WE, Aleman BM, van Leeuwen FE.

JAMA Intern Med. 2015 Jun;175(6):1007-17. doi: 10.1001/jamainternmed.2015.1180.

PMID:
25915855
24.

Simple method to estimate mean heart dose from Hodgkin lymphoma radiation therapy according to simulation X-rays.

van Nimwegen FA, Cutter DJ, Schaapveld M, Rutten A, Kooijman K, Krol AD, Janus CP, Darby SC, van Leeuwen FE, Aleman BM.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):153-60. doi: 10.1016/j.ijrobp.2015.02.019.

PMID:
25863762
25.

Melanoma risk after ovarian stimulation for in vitro fertilization.

Spaan M, van den Belt-Dusebout AW, Schaapveld M, Mooij TM, Burger CW, van Leeuwen FE; OMEGA-project group.

Hum Reprod. 2015 May;30(5):1216-28. doi: 10.1093/humrep/dev023. Epub 2015 Mar 4.

PMID:
25743782
26.

Risk of valvular heart disease after treatment for Hodgkin lymphoma.

Cutter DJ, Schaapveld M, Darby SC, Hauptmann M, van Nimwegen FA, Krol AD, Janus CP, van Leeuwen FE, Aleman BM.

J Natl Cancer Inst. 2015 Feb 23;107(4). pii: djv008. doi: 10.1093/jnci/djv008. Print 2015 Apr.

27.

Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma.

van Nimwegen FA, Schaapveld M, Janus CP, Krol AD, Raemaekers JM, Kremer LC, Stovall M, Aleman BM, van Leeuwen FE.

J Clin Oncol. 2014 Oct 10;32(29):3257-63. doi: 10.1200/JCO.2013.54.4379. Epub 2014 Aug 25.

PMID:
25154821
28.

Cardiovascular morbidity and mortality after treatment for ductal carcinoma in situ of the breast.

Boekel NB, Schaapveld M, Gietema JA, Rutgers EJ, Versteegh MI, Visser O, Aleman BM, van Leeuwen FE.

J Natl Cancer Inst. 2014 Aug 15;106(8). pii: dju156. doi: 10.1093/jnci/dju156. Print 2014 Aug.

29.

Risk of multiple primary malignancies following treatment of Hodgkin lymphoma.

van Eggermond AM, Schaapveld M, Lugtenburg PJ, Krol AD, de Boer JP, Zijlstra JM, Raemaekers JM, Kremer LC, Roesink JM, Louwman MW, Aleman BM, van Leeuwen FE.

Blood. 2014 Jul 17;124(3):319-27; quiz 466. doi: 10.1182/blood-2013-10-532184. Epub 2014 Apr 16.

30.

Prognostic value of insulin-like growth factor 1 and insulin-like growth factor binding protein 3 blood levels in breast cancer.

Hartog H, Boezen HM, de Jong MM, Schaapveld M, Wesseling J, van der Graaf WT.

Breast. 2013 Dec;22(6):1155-60. doi: 10.1016/j.breast.2013.07.038. Epub 2013 Aug 19.

PMID:
23968866
31.

Long-term risk of secondary skin cancers after radiation therapy for Hodgkin's lymphoma.

Daniëls LA, Krol AD, Schaapveld M, Putter H, Jansen PM, Marijt EW, van Leeuwen FE, Creutzberg CL.

Radiother Oncol. 2013 Oct;109(1):140-5. doi: 10.1016/j.radonc.2013.06.041. Epub 2013 Aug 7.

PMID:
23932152
32.

Outcomes of a population-based series of early breast cancer patients with micrometastases and isolated tumour cells in axillary lymph nodes.

van der Heiden-van der Loo M, Schaapveld M, Ho VK, Siesling S, Rutgers EJ, Peeters PH.

Ann Oncol. 2013 Nov;24(11):2794-801. doi: 10.1093/annonc/mdt243. Epub 2013 Jul 17.

PMID:
23864096
33.

Risk and prognostic significance of metachronous contralateral testicular germ cell tumours.

Schaapveld M, van den Belt-Dusebout AW, Gietema JA, de Wit R, Horenblas S, Witjes JA, Hoekstra HJ, Kiemeney LA, Louwman WJ, Ouwens GM, Aleman BM, van Leeuwen FE.

Br J Cancer. 2012 Oct 23;107(9):1637-43. doi: 10.1038/bjc.2012.448. Epub 2012 Oct 11.

34.

Safety and cost-effectiveness of shortening hospital follow-up after breast cancer treatment.

Lu W, Greuter MJ, Schaapveld M, Vermeulen KM, Wiggers T, de Bock GH.

Br J Surg. 2012 Sep;99(9):1227-33. doi: 10.1002/bjs.8850. Epub 2012 Jul 24.

PMID:
22828861
35.

Breslow thickness in the Netherlands: a population-based study of 40 880 patients comparing young and elderly patients.

Kruijff S, Bastiaannet E, Francken AB, Schaapveld M, van der Aa M, Hoekstra HJ.

Br J Cancer. 2012 Jul 24;107(3):570-4. doi: 10.1038/bjc.2012.255. Epub 2012 Jun 19.

36.

A randomized phase II study investigating the addition of the specific COX-2 inhibitor celecoxib to docetaxel plus carboplatin as first-line chemotherapy for stage IC to IV epithelial ovarian cancer, Fallopian tube or primary peritoneal carcinomas: the DoCaCel study.

Reyners AK, de Munck L, Erdkamp FL, Smit WM, Hoekman K, Lalisang RI, de Graaf H, Wymenga AN, Polee M, Hollema H, van Vugt MA, Schaapveld M, Willemse PH; DoCaCel Study Group.

Ann Oncol. 2012 Nov;23(11):2896-902. doi: 10.1093/annonc/mds107. Epub 2012 Jun 11.

PMID:
22689176
37.

Burden of testicular, paratesticular and extragonadal germ cell tumours in Europe.

Trama A, Mallone S, Nicolai N, Necchi A, Schaapveld M, Gietema J, Znaor A, Ardanaz E, Berrino F; RARECARE Working Group.

Eur J Cancer. 2012 Jan;48(2):159-69. doi: 10.1016/j.ejca.2011.08.020. Epub 2011 Dec 3. Erratum in: Eur J Cancer. 2013 Feb;49(3):766.

PMID:
22142457
38.

Prostate brachytherapy and second primary cancer risk: a competitive risk analysis.

Hinnen KA, Schaapveld M, van Vulpen M, Battermann JJ, van der Poel H, van Oort IM, van Roermund JG, Monninkhof EM.

J Clin Oncol. 2011 Dec 1;29(34):4510-5. doi: 10.1200/JCO.2011.35.0991. Epub 2011 Oct 24.

PMID:
22025166
39.

Incidence and prognosis of parathyroid gland carcinoma: a population-based study in The Netherlands estimating the preoperative diagnosis.

Schaapveld M, Jorna FH, Aben KK, Haak HR, Plukker JT, Links TP.

Am J Surg. 2011 Nov;202(5):590-7. doi: 10.1016/j.amjsurg.2010.09.025. Epub 2011 Aug 20.

PMID:
21861982
40.

Underuse of long-term routine hospital follow-up care in patients with a history of breast cancer?

Lu W, Jansen L, Schaapveld M, Baas PC, Wiggers T, De Bock GH.

BMC Cancer. 2011 Jun 28;11:279. doi: 10.1186/1471-2407-11-279.

41.

High risk bladder cancer: current management and survival.

Leliveld AM, Bastiaannet E, Doornweerd BH, Schaapveld M, de Jong IJ.

Int Braz J Urol. 2011 Mar-Apr;37(2):203-10; discussion 210-2.

42.

Implementation of trastuzumab in conjunction with adjuvant chemotherapy in the treatment of non-metastatic breast cancer in the Netherlands.

de Munck L, Schaapveld M, Siesling S, Wesseling J, Voogd AC, Tjan-Heijnen VC, Otter R, Willemse PH.

Breast Cancer Res Treat. 2011 Aug;129(1):229-33. doi: 10.1007/s10549-011-1451-0. Epub 2011 Mar 24.

PMID:
21431871
43.

The value of routine physical examination in the follow up of women with a history of early breast cancer.

Lu W, de Bock GH, Schaapveld M, Baas PC, Wiggers T, Jansen L.

Eur J Cancer. 2011 Mar;47(5):676-82. doi: 10.1016/j.ejca.2010.11.006. Epub 2010 Dec 2.

PMID:
21130643
44.

Risk of third malignancies and death after a second malignancy in retinoblastoma survivors.

Marees T, van Leeuwen FE, Schaapveld M, Imhof SM, de Boer MR, Kors WA, Ringens PJ, Moll AC.

Eur J Cancer. 2010 Jul;46(11):2052-8. doi: 10.1016/j.ejca.2010.03.029. Epub 2010 Apr 17.

PMID:
20400293
45.

Effect of hospital characteristics on outcome of patients with gastric cancer: a population based study in North-East Netherlands.

Siemerink EJ, Schaapveld M, Plukker JT, Mulder NH, Hospers GA.

Eur J Surg Oncol. 2010 May;36(5):449-55. doi: 10.1016/j.ejso.2010.03.011. Epub 2010 Apr 15.

PMID:
20399068
46.

Treatment and outcome in muscle invasive bladder cancer: a population-based survey.

Leliveld AM, Doornweerd BH, Bastiaannet E, Schaapveld M, de Jong IJ.

World J Urol. 2010 Aug;28(4):439-44. doi: 10.1007/s00345-010-0546-2. Epub 2010 Apr 10.

PMID:
20383640
47.

Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age.

van der Kolk DM, de Bock GH, Leegte BK, Schaapveld M, Mourits MJ, de Vries J, van der Hout AH, Oosterwijk JC.

Breast Cancer Res Treat. 2010 Dec;124(3):643-51. doi: 10.1007/s10549-010-0805-3. Epub 2010 Mar 4.

PMID:
20204502
48.

The value of surveillance mammography of the contralateral breast in patients with a history of breast cancer.

Lu W, Schaapveld M, Jansen L, Bagherzadegan E, Sahinovic MM, Baas PC, Hanssen LM, van der Mijle HC, Brandenburg JD, Wiggers T, De Bock GH.

Eur J Cancer. 2009 Nov;45(17):3000-7. doi: 10.1016/j.ejca.2009.08.007. Epub 2009 Sep 8.

PMID:
19744851
49.

Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989.

Schaapveld M, Visser O, Siesling S, Schaar CG, Zweegman S, Vellenga E.

Eur J Cancer. 2010 Jan;46(1):160-9. doi: 10.1016/j.ejca.2009.07.006.

PMID:
19682891
50.

Latent Epstein-Barr virus infection of tumor cells in classical Hodgkin's lymphoma predicts adverse outcome in older adult patients.

Diepstra A, van Imhoff GW, Schaapveld M, Karim-Kos H, van den Berg A, Vellenga E, Poppema S.

J Clin Oncol. 2009 Aug 10;27(23):3815-21. doi: 10.1200/JCO.2008.20.5138. Epub 2009 May 26.

PMID:
19470931

Supplemental Content

Loading ...
Support Center